Why Motus GI Stock Is Skyrocketing Today

Motus GI Holdings Inc MOTS shares are trading higher after the company completed the first clinical evaluation of New Pure-Vu Gastro in upper gastrointestinal (GI) procedures to support FDA submission.

This initial clinical evaluation provided insight into the ability of the Pure-Vu Gen 4 Gastro device to navigate and evaluate the entire anatomy in the upper GI tract. 

The procedures in the upper GI tract were efficient for these first-time users, with the upper procedures averaging only 11 minutes. 

Similarly, in the colon, they were able to improve the average Boston Bowel Prep Scale (BBPS) in 9 patients from 5.9 before the use of Pure-Vu to 8.9 after the use of Pure-Vu with total procedure times averaging 24 minutes (the BBPS scale ranges from 0 (extremely dirty) to 9 (pristinely clean). 

Last week, Motus GI announced new clinical data showing a 33% hospital-wide improvement in incomplete bowel prep rate for colonoscopies during a 12-month study assessing the Pure-Vu EVS.

In January, Motus GI initiated a process to explore a range of strategic and financing alternatives and engaged Lake Street Capital Markets as an advisor.

Price Action: MOTS shares are up 48.60% at $1.07 on the last check Wednesday.